Skip to main content
PMC home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2012 Oct 29;30:18–24. doi: 10.1016/S0213-005X(12)70100-3

Immunopathogenesis of 2009 pandemic influenza

Inmunopatogénesis de la gripe pandémica de 2009

Raquel Almansa a,b,c, Jesús F Bermejo-Martín a,b,c,⁎, Raúl Ortiz de Lejarazu Leonardo a,c
PMCID: PMC7130369  PMID: 23116788

Abstract

Three years after the pandemic, major advances have been made in our understanding of the innate and adaptive immune responses to the influenza A(H1N1)pdm09 virus and those responses’ contribution to the immunopathology associated with this infection. Severe disease is characterized by early secretion of proinflammatory and immunomodulatory cytokines. This cytokine secretion persisted in patients with severe viral pneumonia and was directly associated with the degree of viral replication in the respiratory tract. Cytokines play important roles in the antiviral defense, but persistent hypercytokinemia may cause inflammatory tissue damage and participate in the genesis of the respiratory failure observed in these patients. An absence of pre-existing protective antibodies was the rule for both mild and severe cases. A role for pathogenic immunocomplexes has been proposed for this disease. Defective T cell responses characterize severe cases of infection caused by the influenza A(H1N1)pdm09 virus. Immune alterations associated with accompanying conditions such as obesity, pregnancy or chronic obstructive pulmonary disease may interfere with the normal development of the specific response to the virus. The role of host immunogenetic factors associated with disease severity is also discussed in this review. In conclusion, currently available information suggests a complex immunological dysfunction/alteration that characterizes the severe cases of 2009 pandemic influenza. The potential benefits of prophylactic/therapeutic interventions aimed at preventing/correcting such dysfunction warrant investigation.

Keywords: Influenza, H1N1pdm, Innate, Adaptative, Hypercytokinemia, Cross-immunity, T cell, Antibody, Immune dysfunction, Viral escape

References

  • 1.Nicoll A., Coulombier D. Europe's initial experience with pandemic (H1N1) 2009 - mitigation and delaying policies and practices. Euro Surveill. 2009;14:19279. doi: 10.2807/ese.14.29.19279-en. [DOI] [PubMed] [Google Scholar]
  • 2.Health Protection Agency; Health Protection Scotland; National Public Health Service for Wales; HPA Northern Ireland Swine influenza investigation teams Epidemiology of new influenza A (H1N1) virus infection, United Kingdom, April-June 2009. Euro Surveill. 2009;14:19232. [PubMed] [Google Scholar]
  • 3.Gilsdorf A., Poggensee G., Working Group Pandemic Influenza A(H1N1)v Influenza A(H1N1)v in Germany: the first 10,000 cases. Euro Surveill. 2009;14:19318. doi: 10.2807/ese.14.34.19318-en. [DOI] [PubMed] [Google Scholar]
  • 4.Webb S.A., Pettila V., Seppelt I., Bellomo R., Bailey M., Cooper D.J. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med. 2009;361:1925–1934. doi: 10.1056/NEJMoa0908481. [DOI] [PubMed] [Google Scholar]
  • 5.Jain S., Kamimoto L., Bramley A.M., Schmitz A.M., Benoit S.R., Louie J. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361:1935–1944. doi: 10.1056/NEJMoa0906695. [DOI] [PubMed] [Google Scholar]
  • 6.Kumar A., Zarychanski R., Pinto R., Cook D.J., Marshall J., Lacroix J. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. Jama. 2009;302:1872–1879. doi: 10.1001/jama.2009.1496. [DOI] [PubMed] [Google Scholar]
  • 7.Rello J., Rodríguez A., Ibañez P., Socias L., Cebrian J., Marques A., H1N1 SEMICYUC Working Group Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care. 2009;13:R148. doi: 10.1186/cc8044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Vaillant L., La Ruche G., Tarantola A., Barboza P., epidemic intelligence team at InVS Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill. 2009;14:19309. doi: 10.2807/ese.14.33.19309-en. [DOI] [PubMed] [Google Scholar]
  • 9.Viasus D., Paño-Pardo J.R., Pachón J., Campins A., López-Medrano F., Villoslada A. Novel Influenza A (H1N1) Study Group of the Spanish Network for Research in Infectious Diseases (REIPI). Factors associated with severe disease in hospitalized adults with pandemic (H1N1) 2009 in Spain. Clin Microbiol Infect. 2011;17:738–746. doi: 10.1111/j.1469-0691.2010.03362.x. [DOI] [PubMed] [Google Scholar]
  • 10.González-Vélez A.E., Díaz-Agero-Perez C., Robustillo-Rodela A., Cornejo-Gutiérrez A.M., Pita-López M.J., Oliva-Iñíguez L. Factores asociados a ingreso en unidad de cuidados intensivos en pacientes hospitalizados por Influenza pandémica A/H1N1 2009. Med Intensiva. 2011;35:463–469. doi: 10.1016/j.medin.2011.03.007. [DOI] [PubMed] [Google Scholar]
  • 11.Ada G.L., Jones P.D. The immune response to influenza infection. Curr Top Microbiol Immunol. 1986;128:1–54. doi: 10.1007/978-3-642-71272-2_1. [DOI] [PubMed] [Google Scholar]
  • 12.Sanders C.J., Doherty P.C., Thomas P.G. Respiratory epithelial cells in innate immunity to influenza virus infection. Cell Tissue Res. 2011;343:13–21. doi: 10.1007/s00441-010-1043-z. [DOI] [PubMed] [Google Scholar]
  • 13.Cameron M.J., Bermejo-Martin J.F., Danesh A., Muller M.P., Kelvin D.J. Human immunopathogenesis of severe acute respiratory syndrome (SARS) Virus Res. 2008;133:13–19. doi: 10.1016/j.virusres.2007.02.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Cameron C.M., Cameron M.J., Bermejo-Martin J.F., Ran L., Xu L., Turner P.V. Gene expression analysis of host innate immune responses during Lethal H5N1 infection in ferrets. J Virol. 2008;82:11308–11317. doi: 10.1128/JVI.00691-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Bermejo-Martin J.F., García-Arevalo M.C., Alonso A., De Lejarazu R.O., Pino M., Resino S. Persistence of proinflammatory response after severe respiratory syncytial virus disease in children. J Allergy Clin Immunol. 2007;119:1547–1550. doi: 10.1016/j.jaci.2007.03.014. [DOI] [PubMed] [Google Scholar]
  • 16.Cameron M.J., Ran L., Xu L., Danesh A., Bermejo-Martin J.F., Cameron C.M. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol. 2007;81:8692–8706. doi: 10.1128/JVI.00527-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.De Jong M.D., Simmons C.P., Thanh T.T., Hien V.M., Smith G.J., Chau T.N. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12:1203–1207. doi: 10.1038/nm1477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Osterlund P., Pirhonen J., Ikonen N., Ronkko E., Strengell M., Makela S.M. Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons. J Virol. 2010;84:1414–1422. doi: 10.1128/JVI.01619-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Zeng H., Pappas C., Katz J.M., Tumpey T.M. The 2009 pandemic H1N1 and triplereassortant swine H1N1 influenza viruses replicate efficiently but elicit an attenuated inflammatory response in polarized human bronchial epithelial cells. J Virol. 2011;85:686–696. doi: 10.1128/JVI.01568-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Bermejo-Martín J.F., Ortiz de Lejarazu R., Pumarola T., Rello J., Almansa R., Ramírez P. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care. 2009;13:R201. doi: 10.1186/cc8208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.To K.K., Hung I.F., Li I.W., Lee K.L., Koo C.K., Yan W.W. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis. 2010;50:850–859. doi: 10.1086/650581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Hagau N., Slavcovici A., Gonganau D.N., Oltean S., Dirzu D.S., Brezoszki E.S. Clinical aspects and cytokine response in severe H1N1 influenza A virus infection. Crit Care. 2010;14:R203. doi: 10.1186/cc9324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Arankalle V.A., Lole K.S., Arya R.P., Tripathy A.S., Ramdasi A.Y., Chadha M.S. Role of host immune response and viral load in the differential outcome of pandemic H1N1 (2009) influenza virus infection in Indian patients. PLoS One. 2010:5. doi: 10.1371/journal.pone.0013099. pii: e13099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Julkunen I., Sareneva T., Pirhonen J., Ronni T., Melen K., Matikainen S. Molecular pathogenesis of influenza A virus infection and virus-induced regulation of cytokine gene expression. Cytokine Growth Factor Rev. 2001;12:171–180. doi: 10.1016/s1359-6101(00)00026-5. [DOI] [PubMed] [Google Scholar]
  • 25.Strieter R.M., Belperio J.A., Keane M.P. Host innate defenses in the lung: the role of cytokines. Curr Opin Infect Dis. 2003;16:193–198. doi: 10.1097/00001432-200306000-00002. [DOI] [PubMed] [Google Scholar]
  • 26.Flynn K.J., Belz G.T., Altman J.D., Ahmed R., Woodland D.L., Doherty P.C. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity. 1998;8:683–691. doi: 10.1016/s1074-7613(00)80573-7. [DOI] [PubMed] [Google Scholar]
  • 27.Fietta P., Delsante G. The effector T helper cell triade. Riv Biol. 2009;102:61–74. [PubMed] [Google Scholar]
  • 28.Nalbandian A., Crispin J.C., Tsokos G.C. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol. 2009;157:209–215. doi: 10.1111/j.1365-2249.2009.03944.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Korn T., Oukka M., Kuchroo V., Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol. 2007;19:362–371. doi: 10.1016/j.smim.2007.10.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Louten J., Boniface K., De Waal Malefyt R. Development and function of TH17 cells in health and disease. J Allergy Clin Immunol. 2009;123:1004–1011. doi: 10.1016/j.jaci.2009.04.003. [DOI] [PubMed] [Google Scholar]
  • 31.Toh H.C., Sun L., Soe Y., Wu Y., Phoon Y.P., Chia W.K. G-CSF induces a potentially tolerant gene and immunophenotype profile in T cells in vivo. Clin Immunol. 2009 Jul;132:83–92. doi: 10.1016/j.clim.2009.03.509. [DOI] [PubMed] [Google Scholar]
  • 32.Almansa R., Socias L., Ramirez P., Martin-Loeches I., Vallés J., Loza A. Imbalanced pro- and anti-Th17 responses (IL-17/granulocyte colony-stimulating factor) predict fatal outcome in 2009 pandemic influenza. Crit Care. 2011;15:448. doi: 10.1186/cc10426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Bautista E., Chotpitayasunondh T., Gao Z., Harper S.A., Shaw M., Uyeki T.M. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362:1708–1719. doi: 10.1056/NEJMra1000449. [DOI] [PubMed] [Google Scholar]
  • 34.Paquette S.G., Banner D., Zhao Z., Fang Y., Huang S.S., Leomicronn A.J. Interleukin-6 Is a Potential Biomarker for Severe Pandemic H1N1 Influenza A Infection. PLoS One. 2012;7:e38214. doi: 10.1371/journal.pone.0038214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Zúñiga J., Torres M., Romo J., Torres D., Jiménez L., Ramírez G. Inflammatory profiles in severe pneumonia associated with the pandemic influenza A/H1N1 virus isolated in Mexico City. Autoimmunity. 2011;44:562–570. doi: 10.3109/08916934.2011.592885. [DOI] [PubMed] [Google Scholar]
  • 36.Bermejo-Martín J.F., Martín-Loeches I., Rello J., Antón A., Almansa R., Xu L. Host adaptive immunity deficiency in severe pandemic influenza. Crit Care. 2010;14:R167. doi: 10.1186/cc9259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Zhang Y., Li J., Zhan Y., Wu L., Yu X., Zhang W. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun. 2004 Aug;72:4410–4415. doi: 10.1128/IAI.72.8.4410-4415.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Huang K.J., Su I.J., Theron M., Wu Y.C., Lai S.K., Liu C.C. An interferon-gammarelated cytokine storm in SARS patients. J Med Virol. 2005;75:185–194. doi: 10.1002/jmv.20255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Skoner D.P., Gentile D.A., Patel A., Doyle W.J. Evidence for cytokine mediation of disease expression in adults experimentally infected with influenza A virus. J Infect Dis. 1999;180:10–14. doi: 10.1086/314823. [DOI] [PubMed] [Google Scholar]
  • 40.Gentile D., Doyle W., Whiteside T., Fireman P., Hayden F.G., Skoner D. Increased interleukin-6 levels in nasal lavage samples following experimental influenza A virus infection. Clin Diagn Lab Immunol. 1998;5:604–608. doi: 10.1128/cdli.5.5.604-608.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Fritz R.S., Hayden F.G., Calfee D.P., Cass L.M., Peng A.W., Alvord W.G. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis. 1999;180:586–593. doi: 10.1086/314938. [DOI] [PubMed] [Google Scholar]
  • 42.Pavlisa G., Pavlisa G., Kusec V., Kolonic S.O., Markovic A.S., Jaksic B. Serum levels of VEGF and bFGF in hypoxic patients with exacerbated COPD. Eur Cytokine Netw. 2010;21:92–98. doi: 10.1684/ecn.2010.0193. Jun. [DOI] [PubMed] [Google Scholar]
  • 43.Kilani M.M., Mohammed K.A., Nasreen N., Hardwick J.A., Kaplan M.H., Tepper R.S. Respiratory syncytial virus causes increased bronchial epithelial permeability. Chest. 2004;126:186–191. doi: 10.1378/chest.126.1.186. [DOI] [PubMed] [Google Scholar]
  • 44.Venteclef N., Delerive P. Interleukin-1 receptor antagonist induction as an additional mechanism for liver receptor homolog-1 to negatively regulate the hepatic acute phase response. J Biol Chem. 2007;282:4393–4399. doi: 10.1074/jbc.M608993200. [DOI] [PubMed] [Google Scholar]
  • 45.McKinstry K.K., Strutt T.M., Buck A., Curtis J.D., Dibble J.P., Huston G. IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol. 2009;182:7353–7363. doi: 10.4049/jimmunol.0900657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Hale B.G., Albrecht R.A., Garcia-Sastre A. Innate immune evasion strategies of influenza viruses. Future Microbiol. 2010;5:23–41. doi: 10.2217/fmb.09.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Liang M., Lye D.C., Chen M.I., Chow A., Krishnan P., Seow E. New influenza A (H1N1) 2009 in Singapore: the first ten adult imported cases. Singapore Med J. 2009;50:581–583. [PubMed] [Google Scholar]
  • 48.Ling L.M., Chow A.L., Lye D.C., Tan A.S., Krishnan P., Cui L. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis. 2010;50:963–969. doi: 10.1086/651083. [DOI] [PubMed] [Google Scholar]
  • 49.Lee N., Chan P.K., Wong C.K., Wong K.T., Choi K.W., Joynt G.M. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther. 2011;16:237–247. doi: 10.3851/IMP1722. [DOI] [PubMed] [Google Scholar]
  • 50.Lee N., Chan P.K., Hui D.S., Rainer T.H., Wong E., Choi K.W. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200:492–500. doi: 10.1086/600383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Almansa R., Anton A., Ramirez P., Martin-Loeches I., Banner D., Pumarola T. Direct association between pharyngeal viral secretion and host cytokine response in severe pandemic influenza. BMC Infect Dis. 2010;11:232. doi: 10.1186/1471-2334-11-232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Chowell G., Bertozzi S.M., Colchero M.A., Lopez-Gatell H., Alpuche-Aranda C., Hernandez M. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med. 2009;361:674–679. doi: 10.1056/NEJMoa0904023. [DOI] [PubMed] [Google Scholar]
  • 53.Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361:1945–1952. doi: 10.1056/NEJMoa0906453. [DOI] [PubMed] [Google Scholar]
  • 54.Miller E., Hoschler K., Hardelid P., Stanford E., Andrews N., Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010;375:1100–1108. doi: 10.1016/S0140-6736(09)62126-7. [DOI] [PubMed] [Google Scholar]
  • 55.Booy R., Khandaker G., Heron L.G., Yin J., Doyle B., Tudo K.K. Cross-reacting antibodies against the pandemic (H1N1) 2009 influenza virus in older Australians. Med J Aust. 2011;194:19–23. doi: 10.5694/j.1326-5377.2011.tb04139.x. [DOI] [PubMed] [Google Scholar]
  • 56.Cherian S., Shil P., Mishra A.C. Antigen-Antibody docking reveals the molecular basis for cross-reactivity of the 1918 and 2009 Influenza A/H1N1 pandemic viruses. Bioinformation. 2011;6:35–38. doi: 10.6026/97320630006035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Zhang W., Qi J., Shi Y., Li Q., Gao F., Sun Y. Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus. Protein Cell. 2010;1:459–467. doi: 10.1007/s13238-010-0059-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Miotto O., Heiny A.T., Albrecht R., García-Sastre A., Tan T.W., August J.T. Completeproteome mapping of human influenza A adaptive mutations: implications for human transmissibility of zoonotic strains. PLoS One. 2010;5:e9025. doi: 10.1371/journal.pone.0009025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Monsalvo A.C., Batalle J.P., Lopez M.F., Krause J.C., Klemenc J., Hernandez J.Z. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med. 2010;17:195–199. doi: 10.1038/nm.2262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Ge X., Tan V., Bollyky P.L., Standifer N.E., James E.A., Kwok W.W. Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swineorigin influenza A virus. J Virol. 2010 Apr;84:3312–3319. doi: 10.1128/JVI.02226-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Tu W., Mao H., Zheng J., Liu Y., Chiu S.S., Qin G. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol. 2010;84:6527–6535. doi: 10.1128/JVI.00519-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Rygiel T.P., Rijkers E.S., De Ruiter T., Stolte E.H., Van der Valk M., Rimmelzwaan G.F. Lack of CD200 enhances pathological T cell responses during influenza infection. J Immunol. 2009;183:1990–1996. doi: 10.4049/jimmunol.0900252. [DOI] [PubMed] [Google Scholar]
  • 63.Ramana C.V., Cheng G.S., Kumar A., Kwon H.J., Enelow R.I. Role of alveolar epithelial early growth response-1 (Egr-1) in CD8+ T cell-mediated lung injury. Mol Immunol. 2009;47:623–631. doi: 10.1016/j.molimm.2009.09.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Le Goffic R., Balloy V., Lagranderie M., Alexopoulou L., Escriou N., Flavell R. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virusinduced acute pneumonia. PLoS Pathog. 2006 Jun;2:e53. doi: 10.1371/journal.ppat.0020053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Mauad T., Hajjar L.A., Callegari G.D., Da Silva L.F., Schout D., Galas F.R. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med. 2010;181:72–79. doi: 10.1164/rccm.200909-1420OC. [DOI] [PubMed] [Google Scholar]
  • 66.Agrati C., Gioia C., Lalle E., Cimini E., Castilletti C., Armignacco O. Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J Infect Dis. 2010;202:681–689. doi: 10.1086/655469. [DOI] [PubMed] [Google Scholar]
  • 67.Giamarellos-Bourboulis E.J., Raftogiannis M., Antonopoulou A., Baziaka F., Koutoukas P., Savva A. Effect of the novel influenza A (H1N1) virus in the human immune system. PLoS One. 2009;4:e8393. doi: 10.1371/journal.pone.0008393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Jamieson D.J., Honein M.A., Rasmussen S.A., Williams J.L., Swerdlow D.L., Biggerstaff M.S. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet. 2009;374:451–458. doi: 10.1016/S0140-6736(09)61304-0. [DOI] [PubMed] [Google Scholar]
  • 69.Louie J.K., Acosta M., Jamieson D.J., Honein M.A. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med. 2010;362:27–35. doi: 10.1056/NEJMoa0910444. [DOI] [PubMed] [Google Scholar]
  • 70.Louie J.K., Wadford D.A., Norman A., Jamieson D.J. 2009 pandemic influenza A (H1N1) and vaccine failure in pregnancy. Obstet Gynecol. 2011;117(2 Pt 2):470–472. doi: 10.1097/AOG.0b013e3181fd2e38. [DOI] [PubMed] [Google Scholar]
  • 71.Morgan O.W., Bramley A., Fowlkes A., Freedman D.S., Taylor T.H., Gargiullo P. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS One. 2010;5:e9694. doi: 10.1371/journal.pone.0009694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Louie J.K., Acosta M., Samuel M.C., Schechter R., Vugia D.J., Harriman K. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1) Clin Infect Dis. 2011;52:301–312. doi: 10.1093/cid/ciq152. [DOI] [PubMed] [Google Scholar]
  • 73.Almansa R., Sanchez-Garcia M., Herrero A., Calzada S., Roig V., Barbado J. Host response cytokine signatures in viral and nonviral acute exacerbations of chronic obstructive pulmonary disease. J Interferon Cytokine Res. 2011;31:409–413. doi: 10.1089/jir.2010.0131. [DOI] [PubMed] [Google Scholar]
  • 74.Smith A.G., Sheridan P.A., Tseng R.J., Sheridan J.F., Beck M.A. Selective impairment in dendritic cell function and altered antigen-specific CD8+ T-cell responses in dietinduced obese mice infected with influenza virus. Immunology. 2009;126:268–279. doi: 10.1111/j.1365-2567.2008.02895.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Bauer C.M., Zavitz C.C., Botelho F.M., Lambert K.N., Brown E.G., Mossman K.L. Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS One. 2011;5:e13251. doi: 10.1371/journal.pone.0013251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Nave H., Beutel G., Kielstein J.T. Obesity-related immunodeficiency in patients with pandemic influenza H1N1. Lancet Infect Dis. 2011;11:14–15. doi: 10.1016/S1473-3099(10)70304-2. [DOI] [PubMed] [Google Scholar]
  • 77.Easterbrook J.D., Dunfee R.L., Schwartzman L.M., Jagger B.W., Sandouk A., Kash J.C. Obese mice have increased morbidity and mortality compared to non-obese mice during infection with the 2009 pandemic H1N1 influenza virus. Influenza Other Respi Viruses. 2011;5:418–425. doi: 10.1111/j.1750-2659.2011.00254.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Jamieson D.J., Ellis J.E., Jernigan D.B., Treadwell T.A. Emerging infectious disease outbreaks: old lessons and new challenges for obstetrician-gynecologists. Am J Obstet Gynecol. 2006;194:1546–1555. doi: 10.1016/j.ajog.2005.06.062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Uchide N., Ohyama K., Bessho T., Toyoda H. Induction of pro-inflammatory cytokine gene expression and apoptosis in human chorion cells of fetal membranes by influenza virus infection: possible implications for maintenance and interruption of pregnancy during infection. Med Sci Monit. 2005;11:RA7–RA16. [PubMed] [Google Scholar]
  • 80.Kraus T.A., Sperling R.S., Engel S.M., Lo Y., Kellerman L., Singh T. Peripheral blood cytokine profiling during pregnancy and post-partum periods. Am J Reprod Immunol. 2010;64:411–426. doi: 10.1111/j.1600-0897.2010.00889.x. [DOI] [PubMed] [Google Scholar]
  • 81.Chan K.H., Zhang A.J., To K.K., Chan C.C., Poon V.K., Guo K. Wild type and mutant 2009 pandemic influenza A (H1N1) viruses cause more severe disease and higher mortality in pregnant BALB/c mice. PLoS One. 2010;5:e13757. doi: 10.1371/journal.pone.0013757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Marcelin G., Aldridge J.R., Duan S., Ghoneim H.E., Rehg J., Marjuki H. Fatal outcome of pandemic H1N1 2009 influenza virus infection is associated with immunopathology and impaired lung repair, not enhanced viral burden, in pregnant mice. J Virol. 2011;85:11208–11219. doi: 10.1128/JVI.00654-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Juno J., Fowke K.R., Keynan Y. Immunogenetic factors associated with severe respiratory illness caused by zoonotic H1N1 and H5N1 influenza viruses. Clin Dev Immunol. 2011;2012:797180. doi: 10.1155/2012/797180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Martin-Loeches I., Lisboa T., Rhodes A., Moreno R.P., Silva E., Sprung C. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med. 2011;37:272–283. doi: 10.1007/s00134-010-2078-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Kim S.H., Hong S.B., Yun S.C., Choi W.I., Ahn J.J., Lee Y.J. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med. 2011;183:1207–1214. doi: 10.1164/rccm.201101-0110OC. [DOI] [PubMed] [Google Scholar]
  • 86.Brun-Buisson C., Richard J.C., Mercat A., Thiebaut A.C., Brochard L. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med. 2011;183:1200–1206. doi: 10.1164/rccm.201101-0135OC. [DOI] [PubMed] [Google Scholar]
  • 87.Adcock I.M., Chou P.C., Durham A., Ford P. Overcoming steroid unresponsiveness in airways disease. Biochem Soc Trans. 2009;37(Pt 4):824–829. doi: 10.1042/BST0370824. [DOI] [PubMed] [Google Scholar]
  • 88.Adcock I.M., Barnes P.J. Molecular mechanisms of corticosteroid resistance. Chest. 2008 Aug;134:394–401. doi: 10.1378/chest.08-0440. [DOI] [PubMed] [Google Scholar]
  • 89.Min J.Y., Jang Y.J. Macrolide therapy in respiratory viral infections. Mediators Inflamm. 2012:649570. doi: 10.1155/2012/649570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Bermejo-Martin J.F., Kelvin D.J., Eiros J.M., Castrodeza J., Ortiz de Lejarazu R. Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains. J Infect Dev Ctries. 2009;3:159–161. doi: 10.3855/jidc.18. [DOI] [PubMed] [Google Scholar]
  • 91.Sawabuchi T., Suzuki S., Iwase K., Ito C., Mizuno D., Togari H. Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza. Respirology. 2009 Nov;14:1173–1179. doi: 10.1111/j.1440-1843.2009.01639.x. [DOI] [PubMed] [Google Scholar]
  • 92.Hung I.F., To K.K., Lee C.K., Lee K.L., Chan K., Yan W.W. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52:447–456. doi: 10.1093/cid/ciq106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Takeda S., Munakata R., Abe S., Mii S., Suzuki M., Kashiwada T. Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intensive Care Med. 2010;36:906–907. doi: 10.1007/s00134-010-1830-8. [DOI] [PubMed] [Google Scholar]
  • 94.Alleva L.M., Budd A.C., Clark I.A. Systemic release of high mobility group box 1 protein during severe murine influenza. J Immunol. 2008;181:1454–1459. doi: 10.4049/jimmunol.181.2.1454. [DOI] [PubMed] [Google Scholar]
  • 95.Fedson D.S. Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis. 2008;8:571–576. doi: 10.1016/S1473-3099(08)70070-7. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Enfermedades Infecciosas Y Microbiologia Clinica are provided here courtesy of Elsevier

RESOURCES